Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 23, Issue 22, 2017, Pages 3954-3963

  Utzeri, Erika ^a   Usai, Paolo ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Endotoxaemia; Intestinal barrier; Intestinal permeability; Microbiota Metabolic syndrome; Non steroidal anti inflammatory drugs; Non steroidal anti inflammatory drugs enteropathy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Proton pump inhibitors

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; LIPOPOLYSACCHARIDE; NONSTEROID ANTIINFLAMMATORY AGENT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ADVERSE OUTCOME; BILE ACID METABOLISM; DRUG EFFECT; ENDOPLASMIC RETICULUM STRESS; ENTEROPATHY; ENZYME INHIBITION; FIBROGENESIS; HUMAN; ILEUM MUCOSA; INNATE IMMUNITY; INSULIN RESISTANCE; INTESTINAL BARRIER; INTESTINE FLORA; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; INTESTINE PARAMETERS; JEJUNUM MUCOSA; LIPOGENESIS; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PEER REVIEW; REVIEW; STATIC ELECTRICITY; TIGHT JUNCTION; WEIGHT GAIN; ANIMAL; BACTERIAL TRANSLOCATION; BODY WEIGHT GAIN; CHEMICALLY INDUCED; DRUG EFFECTS; INTESTINE MUCOSA; LIVER; METABOLISM; MICROBIOLOGY; PERMEABILITY; RISK FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BACTERIAL TRANSLOCATION; GASTROINTESTINAL MICROBIOME; HUMANS; INSULIN RESISTANCE; INTESTINAL DISEASES; INTESTINAL MUCOSA; LIPOGENESIS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATIVE STRESS; PERMEABILITY; RISK FACTORS; TIGHT JUNCTIONS; WEIGHT GAIN;

EID: 85020545614     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i22.3954     Document Type: Review

References (88)

1. Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, Gumpel MJ, Bjarnason I. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998; 43: 506-511 [PMID: 9824578]
2. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 2006; 82: 186-191 [PMID: 16517800 DOI: 10.1136/pgmj.2005.039586]
3. Lanas A, Panés J, Piqué JM. Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 2003; 9: 2253-2266 [PMID: 14529405]
4. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-59 [PMID: 15645405]
5. Lanas A, Sopeña F. Nonsteroidal anti-inflammatory drugs and lower gastrointestinal complications. Gastroenterol Clin North Am 2009; 38: 333-352 [PMID: 19446262 DOI: 10.1016/ j.gtc.2009.03.007]
6. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993; 104: 1832-1847 [PMID: 8500743]
7. Davies NM, Saleh JY, Skjodt NM. Detection and prevention of NSAID-induced enteropathy. J Pharm Pharm Sci 2000; 3: 137-155 [PMID: 10954683]
8. Scarpignato C, Hunt RH. Nonsteroidal antiinflammatory drugrelated injury to the gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin North Am 2010; 39: 433-464 [PMID: 20951911 DOI: 10.1016/j.gtc.2010.08.010]
9. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-141 [PMID: 15704047]
10. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-1178 [PMID: 15887101]
11. Maiden L. Capsule endoscopic diagnosis of nonsteroidal antiinflammatory drug-induced enteropathy. J Gastroenterol 2009; 44 Suppl 19: 64-71 [PMID: 19148796 DOI: 10.1007/ s00535-008-2248-8]
12. Fujimori S, Gudis K, Takahashi Y, Seo T, Yamada Y, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C. Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest 2010; 40: 504-510 [PMID: 20412292 DOI: 10.1111/ j.1365-2362.2010.02290.x]
13. Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet 2007; 369: 614 [PMID: 17307109 DOI: 10.1016/ S0140-6736(07)60282-7]
14. Higuchi K, Umegaki E, Watanabe T, Yoda Y, Morita E, Murano M, Tokioka S, Arakawa T. Present status and strategy of NSAIDsinduced small bowel injury. J Gastroenterol 2009; 44: 879-888 [PMID: 19568687 DOI: 10.1007/s00535-009-0102-2]
15. Lanas A, García-Rodríguez LA, Polo-Tomás M, Ponce M, Alonso- Abreu I, Perez-Aisa MA, Perez-Gisbert J, Bujanda L, Castro M, Muñoz M, Rodrigo L, Calvet X, Del-Pino D, Garcia S. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104: 1633-1641 [PMID: 19574968 DOI: 10.1038/ajg.2009.164]
16. Minemura M, Shimizu Y. Gut microbiota and liver diseases. World J Gastroenterol 2015; 21: 1691-1702 [PMID: 25684933 DOI: 10.3748/wjg.v21.i6.1691]
17. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-235 [PMID: 5284360]
18. Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009; 44 Suppl 19: 23-29 [PMID: 19148789 DOI: 10.1007/ s00535-008-2266-6]
19. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu Q, Bombardier C. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-292 [PMID: 12557133 DOI: 10.1053/gast.2003.50054]
20. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmod T, Scott D, Wrigglesworth JM, Bjarnason I. Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344-353 [PMID: 9378390]
21. Boelsterli UA, Redinbo MR, Saitta KS. Multiple NSAID-induced hits injure the small intestine: underlying mechanisms and novel strategies. Toxicol Sci 2013; 131: 654-667 [PMID: 23091168 DOI: 10.1093/toxsci/kfs310]
22. McCormack K, Brune K. Classical absorption theory and the development of gastric mucosal damage associated with the nonsteroidal anti-inflammatory drugs. Arch Toxicol 1987; 60: 261-269 [PMID: 3307703]
23. Rainsford KD, Bjarnason I. NSAIDs: take with food or after fasting? J Pharm Pharmacol 2012; 64: 465-469 [PMID: 22420652 DOI: 10.1111/j.2042-7158.2011.01406.x]
24. Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, Aristorena JC, Pla-Delfina JM. Pharmacokinetics and bioavailability of diclofenac in the rat. J Pharmacokinet Biopharm 1991; 19: 647-665 [PMID: 1815046]
25. King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 2001; 61: 49-53 [PMID: 11294973]
26. Mohri K, Okada K, Benet LZ. Stereoselective metabolism of benoxaprofen in rats. Biliary excretion of benoxaprofen taurine conjugate and glucuronide. Drug Metab Dispos 1998; 26: 332-337 [PMID: 9531520]
27. Seitz S, Boelsterli UA. Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats. Gastroenterology 1998; 115: 1476-1482 [PMID: 9834275]
28. Lagas JS, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH. Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters. Mol Pharmacol 2010; 77: 687-694 [PMID: 20086033 DOI: 10.1124/mol.109.062364]
29. Boelsterli UA, Ramirez-Alcantara V. NSAID acyl glucuronides and enteropathy. Curr Drug Metab 2011; 12: 245-252 [PMID: 21395536]
30. Bjarnason I, Smethurst P, Macpherson A, Walker F, McElnay JC, Passmore AP, Menzies IS. Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 1992; 102: 1546-1550 [PMID: 1568563]
31. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190-1200 [PMID: 22408036 DOI: 10.1093/ eurheartj/ehr453]
32. Ramirez-Alcantara V, LoGuidice A, Boelsterli UA. Protection from diclofenac-induced small intestinal injury by the JNK inhibitor SP600125 in a mouse model of NSAID-associated enteropathy. Am J Physiol Gastrointest Liver Physiol 2009; 297: G990-G998 [PMID: 20501447]
33. LoGuidice A, Ramirez-Alcantara V, Proli A, Gavillet B, Boelsterli UA. Pharmacologic targeting or genetic deletion of mitochondrial cyclophilin D protects from NSAID-induced small intestinal ulceration in mice. Toxicol Sci 2010; 118: 276-285 [PMID: 20668000 DOI: 10.1093/toxsci/kfq226]
34. Watanabe T, Tanigawa T, Nadatani Y, Otani K, Machida H, Okazaki H, Yamagami H, Watanabe K, Tominaga K, Fujiwara Y, Arakawa T. Mitochondrial disorders in NSAIDs-induced small bowel injury. J Clin Biochem Nutr 2011; 48: 117-121 [PMID: 21373263 DOI: 10.3164/jcbn.10-73]
35. Tsutsumi S, Gotoh T, Tomisato W, Mima S, Hoshino T, Hwang HJ, Takenaka H, Tsuchiya T, Mori M, Mizushima T. Endoplasmic reticulum stress response is involved in nonsteroidal antiinflammatory drug-induced apoptosis. Cell Death Differ 2004; 11: 1009-1016 [PMID: 15131590 DOI: 10.1038/sj.cdd.4401436]
36. Tanaka K, Tomisato W, Hoshino T, Ishihara T, Namba T, Aburaya M, Katsu T, Suzuki K, Tsutsumi S, Mizushima T. Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory druginduced apoptosis. J Biol Chem 2005; 280: 31059-31067 [PMID: 15987693 DOI: 10.1074/jbc.M502956200]
37. Nakanishi Y, Matsushita A, Matsuno K, Iwasaki K, Utoh M, Nakamura C, Uno Y. Regional distribution of cytochrome p450 mRNA expression in the liver and small intestine of cynomolgus monkeys. Drug Metab Pharmacokinet 2010; 25: 290-297 [PMID: 20610888]
38. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T. Non-steroidal anti-inflammatory druginduced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008; 57: 181-187 [PMID: 17639086 DOI: 10.1136/ gut.2007.125963]
39. Mahmud T, Scott DL, Bjarnason I. A unifying hypothesis for the mechanism of NSAID related gastrointestinal toxicity. Ann Rheum Dis 1996; 55: 211-213 [PMID: 8733435]
40. Sandoval-Acuña C, Lopez-Alarcón C, Aliaga ME, Speisky H. Inhibition of mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection by quercetin via a coenzyme Q-like action. Chem Biol Interact 2012; 199: 18-28 [PMID: 22652335 DOI: 10.1016/j.cbi.2012.05.006]
41. Lichtenberger LM, Zhou Y, Jayaraman V, Doyen JR, O'Neil RG, Dial EJ, Volk DE, Gorenstein DG, Boggara MB, Krishnamoorti R. Insight into NSAID-induced membrane alterations, pathogenesis and therapeutics: characterization of interaction of NSAIDs with phosphatidylcholine. Biochim Biophys Acta 2012; 1821: 994-1002 [PMID: 22521764 DOI: 10.1016/j.bbalip.2012.04.002]
42. Baines CP. The molecular composition of the mitochondrial permeability transition pore. J Mol Cell Cardiol 2009; 46: 850-857 [PMID: 19233198 DOI: 10.1016/j.yjmcc.2009.02.007]
43. Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 2009; 46: 821-831 [PMID: 19265700 DOI: 10.1016/j.yjmcc.2009.02.021]
44. Nazli A, Yang PC, Jury J, Howe K, Watson JL, Söderholm JD, Sherman PM, Perdue MH, McKay DM. Epithelia under metabolic stress perceive commensal bacteria as a threat. Am J Pathol 2004; 164: 947-957 [PMID: 14982848 DOI: 10.1016/ S0002-9440(10)63182-3]
45. Bruyère A, Declevès X, Bouzom F, Proust L, Martinet M, Walther B, Parmentier Y. Development of an optimized procedure for the preparation of rat intestinal microsomes: comparison of hepatic and intestinal microsomal cytochrome P450 enzyme activities in two rat strains. Xenobiotica 2009; 39: 22-32 [PMID: 19219745 DOI: 10.1080/00498250802517714]
46. Harusato A, Naito Y, Takagi T, Uchiyama K, Mizushima K, Hirai Y, Yamada S, Tuji T, Yoriki H, Horie R, Inoue K, Fukumoto K, Handa O, Ishikawa T, Kokura S, Minamiyama Y, Ichikawa H, Muto A, Igarashi K, Yoshikawa T. Suppression of indomethacininduced apoptosis in the small intestine due to Bach1 deficiency. Free Radic Res 2011; 45: 717-727 [PMID: 21473739 DOI: 10.310 9/10715762.2011.574287]
47. Ohyama K, Shiokawa A, Ito K, Masuyama R, Ichibangase T, Kishikawa N, Imai K, Kuroda N. Toxicoproteomic analysis of a mouse model of nonsteroidal anti-inflammatory drug-induced gastric ulcers. Biochem Biophys Res Commun 2012; 420: 210-215 [PMID: 22426477 DOI: 10.1016/j.bbrc.2012.03.009]
48. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388: 394-397 [PMID: 9237759 DOI: 10.1038/41131]
49. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-258 [PMID: 9734363]
50. Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, Giroud JP, Chaussade S, Chauvelot-Moachon L. Increase in tumor necrosis factor-alpha production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998; 124: 1385-1394 [PMID: 9723949 DOI: 10.1038/ sj.bjp.0701968]
51. Hobbs SS, Goettel JA, Liang D, Yan F, Edelblum KL, Frey MR, Mullane MT, Polk DB. TNF transactivation of EGFR stimulates cytoprotective COX-2 expression in gastrointestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2011; 301: G220-G229 [PMID: 21566012 DOI: 10.1152/ajpgi.00383.2010]
52. Yamada S, Naito Y, Takagi T, Mizushima K, Hirai Y, Horie R, Fukumoto K, Inoue K, Harusato A, Yoshida N, Uchiyama K, Handa O, Ishikawa T, Konishi H, Wakabayashi N, Yagi N, Kokura S, Kita M, Yoshikawa T. Reduced small-intestinal injury induced by indomethacin in interleukin-17A-deficient mice. J Gastroenterol Hepatol 2011; 26: 398-404 [PMID: 21261732 DOI: 10.1111/ j.1440-1746.2010.06496.x]
53. Jacob M, Foster R, Sigthorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol 2007; 81: 291-298 [PMID: 17151867 DOI: 10.1007/ s00204-006-0149-2]
54. Wax J, Clinger WA, Varner P, Bass P, Winder CV. Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 1970; 58: 772-780 [PMID: 5423889]
55. Lichtenberger LM, Phan T, Okabe S. Aspirin's ability to induce intestinal injury in rats is dependent on bile and can be reversed if pre-associated with phosphatidylcholine. J Physiol Pharmacol 2011; 62: 491-496 [PMID: 22100851]
56. Zhou Y, Dial EJ, Doyen R, Lichtenberger LM. Effect of indomethacin on bile acid-phospholipid interactions: implication for small intestinal injury induced by nonsteroidal antiinflammatory drugs. Am J Physiol Gastrointest Liver Physiol 2010; 298: G722-G731 [PMID: 20203063 DOI: 10.1152/ ajpgi.00387.2009]
57. Dial EJ, Darling RL, Lichtenberger LM. Importance of biliary excretion of indomethacin in gastrointestinal and hepatic injury. J Gastroenterol Hepatol 2008; 23: e384-e389 [PMID: 18086111 DOI: 10.1111/j.1440-1746.2007.05266.x]
58. Barrios JM, Lichtenberger LM. Role of biliary phosphatidylcholine in bile acid protection and NSAID injury of the ileal mucosa in rats. Gastroenterology 2000; 118: 1179-1186 [PMID: 10833493]
59. Robert A, Asano T. Resistance of germfree rats to indomethacininduced intestinal lesions. Prostaglandins 1977; 14: 333-341 [PMID: 331401]
60. Hawksworth G, Drasar BS, Hill MJ. Intestinal bacteria and the hydrolysis of glycosidic bonds. J Med Microbiol 1971; 4: 451-459 [PMID: 5002686 DOI: 10.1099/00222615-4-4-451]
61. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, Redinbo MR. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330: 831-835 [PMID: 21051639 DOI: 10.1126/science.1191175]
62. Lanas A, Scarpignato C. Microbial flora in NSAID-induced intestinal damage: a role for antibiotics? Digestion 2006; 73 Suppl 1: 136-150 [PMID: 16498262 DOI: 10.1159/000089789]
63. Zwolinska-Wcislo M, Krzysiek-Maczka G, Ptak-Belowska A, Karczewska E, Pajdo R, Sliwowski Z, Urbanczyk K, Drozdowicz D, Konturek SJ, Pawlik WW, Brzozowski T. Antibiotic treatment with ampicillin accelerates the healing of colonic damage impaired by aspirin and coxib in the experimental colitis. Importance of intestinal bacteria, colonic microcirculation and proinflammatory cytokines. J Physiol Pharmacol 2011; 62: 357-368 [PMID: 21893697]
64. Montalto M, Gallo A, Curigliano V, D'Onofrio F, Santoro L, Covino M, Dalvai S, Gasbarrini A, Gasbarrini G. Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy - a randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther 2010; 32: 209-214 [PMID: 20384610 DOI: 10.1111/j.1365-2036.2010.04324. x]
65. Montalto M, Gallo A, Gasbarrini A, Landolfi R. NSAID enteropathy: could probiotics prevent it? J Gastroenterol 2013; 48: 689-697 [PMID: 22875474]
66. Scheiman JM, Yeomans ND, Talley NJ, Vakil N, Chan FK, Tulassay Z, Rainoldi JL, Szczepanski L, Ung KA, Kleczkowski D, Ahlbom H, Naesdal J, Hawkey C. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-710 [PMID: 16494585 DOI: 10.1111/j.1572-0241.2006.00499.x]
67. Choung RS, Ruff KC, Malhotra A, Herrick L, Locke GR, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 2011; 33: 1059-1067 [PMID: 21395630 DOI: 10.1111/j.1365-2036.2011.04625.x]
68. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996; 10: 557-561 [PMID: 8853759]
69. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011; 141: 1314-122, 1314-122, [PMID: 21745447 DOI: 10.1053/j.gastro.2011.06.075]
70. Marlicz W, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc 2014; 89: 1699-1709 [PMID: 25440891 DOI: 10.1016/j.mayocp.2014.07.015]
71. Quigley EM. Gut bacteria in health and disease. Gastroenterol Hepatol (N Y) 2013; 9: 560-569 [PMID: 24729765]
72. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-1524 [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020]
73. Sanz Y, Santacruz A, De Palma G. Insights into the roles of gut microbes in obesity. Interdiscip Perspect Infect Dis 2008; 2008: 829101 [PMID: 19259329 DOI: 10.1155/2008/829101]
74. Jiang W, Wu N, Wang X, Chi Y, Zhang Y, Qiu X, Hu Y, Li J, Liu Y. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep 2015; 5: 8096 [PMID: 25644696 DOI: 10.1038/srep08096]
75. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, Keshavarzian A. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008; 28: 1026-1033 [PMID: 18397235 DOI: 10.1111/j.1478-3231.2008.01723.x]
76. Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2013; 17: 533-546, vii [PMID: 24099016 DOI: 10.1016/ j.cld.2013.07.012]
77. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46: 1331-1336 [PMID: 8229111]
78. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330 [PMID: 8229110]
79. Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2003; 7: 435-451 [PMID: 12879993]
80. Farrell GC. Drugs and steatohepatitis. Semin Liver Dis 2002; 22: 185-194 [PMID: 12016549 DOI: 10.1055/s-2002-30106]
81. Geneve J, Hayat-Bonan B, Labbe G, Degott C, Letteron P, Freneaux E, Dinh TL, Larrey D, Pessayre D. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 1987; 242: 1133-1137 [PMID: 3116197]
82. Pessayre D, Fromenty B, Berson A, Robin MA, Lettéron P, Moreau R, Mansouri A. Central role of mitochondria in druginduced liver injury. Drug Metab Rev 2012; 44: 34-87 [PMID: 21892896 DOI: 10.3109/03602532.2011.604086]
83. Fromenty B, Pessayre D. Inhibition of mitochondrial betaoxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995; 67: 101-154 [PMID: 7494860]
84. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in nonalcoholic steatohepatitis. Clin Chim Acta 2011; 412: 1297-1305 [PMID: 21514287 DOI: 10.1016/j.cca.2011.04.013]
85. Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Ohnishi Y. Role of unbalanced growth of gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. J Med Invest 2004; 51: 43-51 [PMID: 15000255]
86. Park SC, Chun HJ, Kang CD, Sul D. Prevention and management of non-steroidal anti-inflammatory drugs-induced small intestinal injury. World J Gastroenterol 2011; 17: 4647-4653 [PMID: 22180706 DOI: 10.3748/wjg.v17.i42.4647]
87. Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinal- sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One 2012; 7: e35196 [PMID: 22496907 DOI: 10.1371/journal.pone.0035196]
88. Rigas B, Kashfi K. Cancer prevention: a new era beyond cyclooxygenase-2. J Pharmacol Exp Ther 2005; 314: 1-8 [PMID: 15805430 DOI: 10.1124/jpet.104.080564]